Priapism at the onset of acute lymphoblastic leukemia in a 12-year-old child

Cover Page

Cite item

Full Text

Abstract

   Acute lymphoblastic leukemia (ALL) is the most common cancer in the clinical practice of pediatric oncology/hematology. At the onset of the disease, patients can develop such a life-threatening complication as hyperleukocytosis with leukostasis that can manifest in many different ways, including ischemic priapism, an extremely rare type of leukostasis in children with ALL. Apart from death associated with hyperleukocytosis caused by the underlying disease, inadequate and poorly timed specific therapy and supportive care can lead to erectile dysfunction, impotence or intermittent priapism in the future. In this article, we report an extremely rare clinical case of ischemic priapism in a 12-year-old patient that developed at the onset of ALL and was the only manifestation of the disease as well as the reason for admission to hospital. The patient's parents gave consent to the use of their child's data, including photographs, for research purposes and in publications. Here, we analyzed special aspects of this complication, described modern treatment strategies and provided an international literature review. We emphasize the importance of urgent care delivery due to the critical prognostic significance of timely and adequate treatment provided by a multidisciplinary team.

About the authors

A. D. Inyoshina

The Almazov National Medical Research Centre of Ministry of Healthcare of the Russian Federation

Email: alisaineshinansk@gmail.com
ORCID iD: 0000-0001-7794-9095

Saint Petersburg

Russian Federation

А. S. Kapustina

The Almazov National Medical Research Centre of Ministry of Healthcare of the Russian Federation

Email: kapustina-annna@yandex.ru
ORCID iD: 0000-0002-6758-1546

Saint Petersburg

Russian Federation

А. Yu. Smirnova

The Almazov National Medical Research Centre of Ministry of Healthcare of the Russian Federation

Email: misha12_09@mail.ru
ORCID iD: 0000-0002-5293-9568

Saint Petersburg

Russian Federation

Е. А. Grin

Center for Endoscopic Urology and New Technologies at the St. Luke Clinical Hospital

Email: sv.lukaendouro@gmail.com
ORCID iD: 0000-0002-8685-6525

Saint Petersburg

Russian Federation

G. G. Baratashvili

The Almazov National Medical Research Centre of Ministry of Healthcare of the Russian Federation

Email: barat777@mail.ru

Saint Petersburg

Russian Federation

I. М. Kagantsov

The Almazov National Medical Research Centre of Ministry of Healthcare of the Russian Federation

Email: ilkagan@rambler.ru
ORCID iD: 0000-0002-3957-1615

Saint Petersburg

Russian Federation

Yu. V. Dinikina

The Almazov National Medical Research Centre of Ministry of Healthcare of the Russian Federation

Author for correspondence.
Email: dinikina_yuv@almazovcentre.ru
ORCID iD: 0000-0002-2003-0982

Yulia V. Dinikina, Cand. Med. Sci., Head of the Department

Department of Chemotherapy for Cancer and Hematologic Diseases and Bone Marrow Transplantation in Children

197341; 2 Akkuratova St., St. Petersburg

Russian Federation

References

  1. Hunger S.P., Mullighan C.G. Acute lymphoblastic leukemia in children. N Engl J Med 2015; 373 (16): 1541–52. doi: 10.1056/NEJMra1400972
  2. Pshonkin A.V., Rumyantseva Yu.V., Litvinov D.V., Karelin A.F., Boychenko E.G., Lagoyko S.N., et al. Treatment of acute lymphoblastic leukemia in adolescents and young adults: the experience of the Moscow–Berlin. Russian Journal of Pediatric Hematology and Oncology 2016; 3 (1): 35–43. doi: 10.17650/2311-1267-2016-3-1-35-43 (In Russ.)
  3. Ganzel C., Becker J., Mintz P.D., Lazarus H.M., Rowe J.M. Hyper-leukocytosis, leukostasis and leukapheresis: practice management. Blood Rev 2012; 26 (3): 117–22. doi: 10.1016/j.blre.2012.01.003
  4. Pham H.P., Schwartz J. How we approach a patient with symptoms of leukostasis requiring emergent leukocytapheresis. Transfusion 2015; 55 (10): 2306–11. doi: 10.1111/trf.13210
  5. Stahl M., Shallis R.M., Wei W., Montesinos P., Lengline E., Neukirchen J., et al. Management of hyper-leukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. Leukemia 2020; 34 (12): 3149–60. doi: 10.1038/s41375-020-0783-3
  6. Spring J., Munshi L. Oncologic Emergencies: Traditional and Contemporary. Crit Care Clin 2021; 37 (1): 85–103. doi: 10.1016/j.ccc.2020.08.004
  7. Zuckerman T., Ganzel C., Tallman M.S., Rowe J.M. How I treat hematologic emergencies in adults with acute leukemia. Blood 2012; 120 (10): 1993–2002. doi: 10.1182/blood-2012-04-424440
  8. Korkmaz S. The management of hyperleukocytosis in 2017: Do we still need leukapheresis? Transfus Apher Sci 2018; 57 (1): 4–7. doi: 10.1016/j.transci.2018.02.006
  9. Porcu P., Cripe L.D., Ng E.W., Bhatia S., Danielson C.M., Orazi A., McCarthy L.J. Hyperleukocytic leukemias and leukostasis: a review of pathophysiology, clinical presentation and management. Leuk Lymphoma 2000; 39 (1–2): 1–18. doi: 10.3109/10428190009053534
  10. Lichtman M.A., Rowe J.M. Hyperleukocytic leukemias: rheological, clinical, and therapeutic considerations. Blood 1982; 60 (2): 279–83.
  11. Stucki A., Rivier A.S., Gikic M., Monai N., Schapira M., Spertini O. Endothelial cell activation by myeloblasts: molecular mechanisms of leukostasis and leukemic cell dissemination. Blood 2001; 97 (7): 2121–9. doi: 10.1182/blood.v97.7.2121
  12. Ganzel C., Becker J., Mintz P.D., Lazarus H.M., Rowe J.M. Hyper-leukocytosis, leukostasis and leukapheresis: practice management. Blood Rev 2012; 26 (3): 117–22. doi: 10.1016/j.blre.2012.01.003
  13. Montague D.K., Jarow J., Broderick G.A., Dmochowski R.R., Heaton J.P., Lue T.F., et al. American Urological Association guideline on the management of priapism. J Urol 2003; 170 (4 Pt 1): 1318–24. doi: 10.1097/01.ju.0000087608.07371.ca
  14. Broderick G.A., Kadioglu A., Bivalacqua T.J., Ghanem H., Nehra A., Shamloul R. Priapism: pathogenesis, epidemiology, and management. J Sex Med 2010; 7 (1 Pt 2): 476–500. doi: 10.1111/j.1743-6109.2009.01625.x
  15. Rodgers R., Latif Z., Copland M. How I manage priapism in chronic myeloid leukaemia patients. Br J Haematol 2012; 158 (2): 155–64. doi: 10.1111/j.1365-2141.2012.09151.x
  16. Vilke G.M., Harrigan R.A., Ufberg J.W., Chan T.C. Emergency evaluation and treatment of priapism. J Emerg Med 2004; 26 (3): 325–9. doi: 10.1016/j.jemermed.2003.12.011
  17. Mulhall J.P., Honig S.C. Priapism: etiology and management. Acad Emerg Med 1996; 3 (8): 810–6. doi: 10.1111/j.1553-2712.1996.tb03520.x
  18. Donaldson J.F., Rees R.W., Steinbrecher H.A. Priapism in children : a comprehensive review and clinical guideline. J Pediatr Urol 2014; 10 (1): 11–24. doi: 10.1016/j.jpurol.2013.07.024
  19. Gokce A., Gul D., Orhan M.F., Büyükavci M., Demir G., Beyaz S.G. Epidural blockade for alternative management of priapism: A case report of child with T-cell acute lymphoblastic leukemia. Urology 2021; 156: e121–3. doi: 10.1016/j.urology.2021.06.017
  20. Vadakan V.V., Ortega J. Priapism in acute lymphoblastic leukemia. Cancer 1972; 30 (2): 373–75. doi: 10.1002/1097-0142(197208)30:2<373::aid-cncr2820300211>3.0.co;2-g
  21. van der Velde M.G.A.M., Tiellemans S.M..B, de Lil H., Nieuwenhuizen L. The value of leukapheresis for treatment of priapism as presenting feature of chronic myeloid leukemia-Case report and review of literature. EJHaem 2022; 3 (4): 1100–15. doi: 10.1002/jha2.545
  22. Röllig C., Ehninger G. How I treat hyperleukocytosis in acute myeloid leukemia. Blood 2015; 125 (21): 3246–52. doi: 10.1182/blood-2014-10-551507
  23. Ruggiero A., Rizzo D., Amato M., Riccardi R. Management of Hyper-leukocytosis. Curr Treat Options Oncol 2016; 17 (2): 7. doi: 10.1007/s11864-015-0387-8
  24. Ganzel C., Becker J., Mintz P.D., Lazarus H.M., Rowe J.M. Hyper-leukocytosis, leukostasis and leukapheresis: practice management. Blood Rev 2012; 26 (3): 117–22. doi: 10.1016/j.blre.2012.01.003
  25. Levey H.R., Segal R.L., Bivalacqua T.J. Management of priapism: an update for clinicians. Ther Adv Urol 2014; 6 (6): 230–44. doi: 10.1177/1756287214542096
  26. Burnett A.L., Sharlip I.D. Standard operating procedures for priapism. J Sex Med 2013; 10 (1): 180–94. doi: 10.1111/j.1743-6109.2012.02707.x
  27. Capece M., Falcone M., Cai T., Palmieri A., Cocci A., La Rocca R. Penile Prosthesis Implantation in Refractory Ischaemic Priapism: Patient Selection and Special Considerations. Res Rep Urol 2022; 14: 1–6. doi: 10.2147/RRU.S278807
  28. Reddy A.G., Alzweri L.M., Gabrielson A.T., Leinwand G., Hellstrom W.J.G. Role of Penile Prosthesis in Priapism: A Review. World J Mens Health 2018; 36 (1): 4–14. doi: 10.5534/wjmh.17040

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2023 Inyoshina A.D., Kapustina А.S., Smirnova А.Y., Grin Е.А., Baratashvili G.G., Kagantsov I.М., Dinikina Y.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.